Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDFB
Discontinued Product
1625 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
说明： Positive allosteric modulator of mGlu5 receptors
别名： 3,3'-Difluorobenzaldazine
化学名： [(3-Fluorophenyl)methylene]hydrazone-3-fluorobenzaldehyde
纯度： ≥99% (HPLC)
生物活性 for DFB
DFB is a novel allosteric potentiator of the metabotropic glutamate receptor mGlu5. Devoid of agonist activity itself, but potentiates (3 - 6-fold) the action of agonists at mGlu5 without any effect at other mGlu subtypes (EC50 for potentiation = 2 - 5.3 μM).
技术数据 for DFB
| 分子量 | 244.24 |
| 公式 | C14H10F2N2 |
| 储存 | Store at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 15332-10-2 |
| PubChem ID | 52942441 |
| InChI Key | DYNGCIHMNWOBSU-MSQVLRTGSA-K |
| Smiles | FC1=CC(=CC=C1)\C=N\N=C\C1=CC=CC(F)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for DFB
参考文献 for DFB
参考文献是支持产品生物活性的出版物。
O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol.Pharmacol. 64 731 PMID: 12920211
Zhang et al (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J.Pharmacol.Exp.Ther. 315 1212 PMID: 16135701
Williams et al (2002) DFB, an allosteric potentiator of mGluR5 4th International Meeting on Metabotropic Glutamat
关键词: DFB, DFB supplier, Allosteric, potentiators, mGlu5, mGluR5, Group, I, Receptors, Glutamate, Metabotropic, PAM, 3,3'-Difluorobenzaldazine, (Metabotropic), 1625, Tocris Bioscience
1 篇 DFB 的引用文献
引用文献是使用了 Tocris 产品的出版物。 DFB 的部分引用包括：
Chen et al (2011) mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptors by PKC dependent pathway. J Biomed Sci 18 19 PMID: 21342491
DFB 的评论
目前没有该产品的评论。 Be the first to review DFB and earn rewards!
Have you used DFB?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.